Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat Rev Cancer, 4, 361, 10.1038/nrc1360 Camidge, 2014, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, 11, 473, 10.1038/nrclinonc.2014.104 Westover, 2018, Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors, Ann Oncol, 29, i10, 10.1093/annonc/mdx703 Lovly, 2014, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies, Clin Cancer Res, 20, 2249, 10.1158/1078-0432.CCR-13-1610 Park, 2013, Safety and feasibility of targeted agent combinations in solid tumours, Nat Rev Clin Oncol, 10, 154, 10.1038/nrclinonc.2012.245 Carlomagno, 2002, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases, Cancer Res, 62, 7284 Mulligan, 2014, RET revisited: expanding the oncogenic portfolio, Nat Rev Cancer, 14, 173, 10.1038/nrc3680 Smolewski, 2006, Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway, Anticancer Drugs, 17, 487, 10.1097/00001813-200606000-00001 Janku, 2014, Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors, Cell Rep, 6, 377, 10.1016/j.celrep.2013.12.035 Janku, 2012, PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations, J Clin Oncol, 30, 777, 10.1200/JCO.2011.36.1196 O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 Carracedo, 2008, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J Clin Invest, 118, 3065 Gild, 2013, Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells, Endocr Relat Cancer, 20, 659, 10.1530/ERC-13-0085 Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Cascone, 2011, Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma, J Clin Invest, 121, 1313, 10.1172/JCI42405 Straussman, 2012, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, 487, 500, 10.1038/nature11183 Cascone, 2017, The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer, Clin Cancer Res, 23, 5489, 10.1158/1078-0432.CCR-16-3216 Wagle, 2014, Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib, Cancer Discov, 4, 546, 10.1158/2159-8290.CD-13-0353 Ravaud, 2017, Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: results of EVAX study, Eur J Cancer, 85, 39, 10.1016/j.ejca.2017.07.031 Bianco, 2008, Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs, Br J Cancer, 98, 923, 10.1038/sj.bjc.6604269 Holden, 2005, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors, Ann Oncol, 16, 1391, 10.1093/annonc/mdi247 Owonikoko, 2015, A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer, Clin Cancer Res, 21, 1859, 10.1158/1078-0432.CCR-14-1998 Farid, 2016, Sarcomas associated with genetic cancer predisposition syndromes: a review, Oncologist, 21, 1002, 10.1634/theoncologist.2016-0079 Ekshyyan, 2013, Dual PI3K/mTOR inhibitors: does p53 modulate response?, Clin Cancer Res, 19, 3719, 10.1158/1078-0432.CCR-13-1291 Li, 2015, Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma, Leukemia, 29, 2113, 10.1038/leu.2015.81 Glubb, 2011, Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer, Clin Cancer Res, 17, 5257, 10.1158/1078-0432.CCR-11-0379 Drilon, 2018, Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Nat Rev Clin Oncol, 15, 151, 10.1038/nrclinonc.2017.175 Subbiah, 2018, Precision targeted therapy with BLU-667 for RET-driven cancers, Cancer Discov, 8, 836, 10.1158/2159-8290.CD-18-0338 Subbiah, 2018, Selective RET kinase inhibition for patients with RET-altered cancers, Ann Oncol, 29, 1869, 10.1093/annonc/mdy137